Filip Josephson

Summary

Affiliation: Karolinska University Hospital
Country: Sweden

Publications

  1. doi CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels
    F Josephson
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Eur J Clin Pharmacol 64:775-81. 2008
  2. doi The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients
    Filip Josephson
    Department of Clinical Pharmacology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 66:349-57. 2010
  3. ncbi CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
    F Josephson
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    Clin Pharmacol Ther 81:708-12. 2007
  4. ncbi Antiretroviral treatment of HIV infection: Swedish recommendations 2007
    Filip Josephson
    Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden
    Scand J Infect Dis 39:486-507. 2007
  5. doi Treatment of HIV infection: Swedish recommendations 2009
    Filip Josephson
    Department of Clinical Pharmacology, Karolinska University Hospital, Sweden
    Scand J Infect Dis 41:788-807. 2009
  6. ncbi Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy
    Olle Karlström
    Department of Infectious Diseases, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    J Acquir Immune Defic Syndr 44:417-22. 2007
  7. doi Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007
    Lars Naver
    Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden
    Scand J Infect Dis 40:451-61. 2008
  8. doi Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2010
    Lars Naver
    Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden
    Scand J Infect Dis 43:411-23. 2011
  9. ncbi Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N
    Katarina Gyllensten
    AIDS 20:1906-7. 2006
  10. ncbi Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz
    Jue Wang
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institute, Stockholm
    Pharmacogenet Genomics 16:191-8. 2006

Detail Information

Publications10

  1. doi CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels
    F Josephson
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Eur J Clin Pharmacol 64:775-81. 2008
    ..Efavirenz is an inducer of CYP3A, whereas the ritonavir-boosted regimens are net inhibitors of CYP3A...
  2. doi The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients
    Filip Josephson
    Department of Clinical Pharmacology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 66:349-57. 2010
    ..The relation between atazanavir-induced hyperbilirubinemia and virological efficacy was also studied...
  3. ncbi CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
    F Josephson
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    Clin Pharmacol Ther 81:708-12. 2007
    ..To clarify the clinical importance of the CYP3A5 polymorphism, further studies should be conducted on saquinavir, dosed to steady state, in the presence of ritonavir boosting...
  4. ncbi Antiretroviral treatment of HIV infection: Swedish recommendations 2007
    Filip Josephson
    Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden
    Scand J Infect Dis 39:486-507. 2007
    ..As in the case of the previous publication, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine, 2001 (see http://www.cebm.net/levels_of_evidence.asp#levels)...
  5. doi Treatment of HIV infection: Swedish recommendations 2009
    Filip Josephson
    Department of Clinical Pharmacology, Karolinska University Hospital, Sweden
    Scand J Infect Dis 41:788-807. 2009
    ..All infants (<1 y) should start antiretroviral therapy, regardless of immune status. Also, absolute CD4+ cell counts, rather than percentage, may be used to guide treatment initiation in children above the age of 5 y...
  6. ncbi Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy
    Olle Karlström
    Department of Infectious Diseases, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    J Acquir Immune Defic Syndr 44:417-22. 2007
    ..To investigate the feasibility of ritonavir-boosted atazanavir monotherapy in HIV-1-infected patients with stable antiretroviral therapy (ART)...
  7. doi Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007
    Lars Naver
    Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden
    Scand J Infect Dis 40:451-61. 2008
    ..The recommendations are evidence graded in accordance with the Oxford Centre for Evidence Based Medicine, 2001 (see http://www.cebm.net/levels_of_evidence.asp#levels)...
  8. doi Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2010
    Lars Naver
    Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden
    Scand J Infect Dis 43:411-23. 2011
    ....
  9. ncbi Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N
    Katarina Gyllensten
    AIDS 20:1906-7. 2006
  10. ncbi Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz
    Jue Wang
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institute, Stockholm
    Pharmacogenet Genomics 16:191-8. 2006
    ....